Laboratory information management system for COVID-19 non-clinical efficacy trial data
- Author:
Suhyeon YOON
1
;
Hyuna NOH
;
Heejin JIN
;
Sungyoung LEE
;
Soyul HAN
;
Sung-Hee KIM
;
Jiseon KIM
;
Jung Seon SEO
;
Jeong Jin KIM
;
In Ho PARK
;
Jooyeon OH
;
Joon-Yong BAE
;
Gee Eun LEE
;
Sun-Je WOO
;
Sun-Min SEO
;
Na-Won KIM
;
Youn Woo LEE
;
Hui Jeong JANG
;
Seung-Min HONG
;
Se-Hee AN
;
Kwang-Soo LYOO
;
Minjoo YEOM
;
Hanbyeul LEE
;
Bud JUNG
;
Sun-Woo YOON
;
Jung-Ah KANG
;
Sang-Hyuk SEOK
;
Yu Jin LEE
;
Seo Yeon KIM
;
Young Been KIM
;
Ji-Yeon HWANG
;
Dain ON
;
Soo-Yeon LIM
;
Sol Pin KIM
;
Ji Yun JANG
;
Ho LEE
;
Kyoungmi KIM
;
Hyo-Jung LEE
;
Hong Bin KIM
;
Jun Won PARK
;
Dae Gwin JEONG
;
Daesub SONG
;
Kang-Seuk CHOI
;
Ho-Young LEE
;
Yang-Kyu CHOI
;
Jung-ah CHOI
;
Manki SONG
;
Man-Seong PARK
;
Jun-Young SEO
;
Ki Taek NAM
;
Jeon-Soo SHIN
;
Sungho WON
;
Jun-Won YUN
;
Je Kyung SEONG
Author Information
- Publication Type:RESEARCH
- From:Laboratory Animal Research 2022;38(2):119-127
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research.
Results:In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research.
Conclusions:This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.
